The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

Novo Nordisk A/S ADR (NVO), a trailblazer in the weight-loss revolution, has endured a bruising 2025. The Danish pharma giant ...

Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...

Live Updates Get The Best Affirm Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top analysis on ...

US stocks drifted higher to more records on a holiday-shortened day of trading. The S&P 500 rose 0.3%. The Dow Jones ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...